There were a significant number of prostate cancer poster presentations today (Saturday), many giving information about small Phase II clinical trials of investigational drugs in advanced and hormone-refractory prostate cancer (HRPC).
Filed under: Drugs in development, Management, Treatment | No Comments »
There was only one significant lecture series on prostate cancer on Friday. This session dealt specifically with prostate cancer in the African-American community. The question posed was, “Prostate cancer in Black Americans: is it a different disease?”
Filed under: Diagnosis, Management, Treatment | 1 Comment »
A study published in the June 1 issue of Cancer Research implies that “the form of tomato product one eats could be the key to unlocking its prostate cancer-fighting potential.” Well maybe, if you happen to be a lab rat! The protective effect of tomato products against prostate cancer has been suggested over and over again, [...]
Filed under: Drugs in development, Living with Prostate Cancer, Prevention, Treatment | No Comments »
An article in the June issue of the Journal of Urology provides guidelines from a PSA Working Group defining criteria related to the calulation and application of PSA doubling times in monitoring biochemical recurrence and for stratification of patients in clinical trials.
Filed under: Drugs in development, Management, Treatment | No Comments »
A new online calculator, developed by a Canadian group, is now available to facilitate discussion between patients and their physicians about the value of a prostate biopsy, based on such data as PSA levels, DRE results, and other information. Use of this calculator requires the patient to have access to his free:total PSA ratio, which is not [...]
Filed under: Diagnosis, Tips | No Comments »
Researchers at the U.S. National Cancer Institute have found no link between vitamin D concentrations in the blood and probability of prostate cancer in men. They had tracked the vitamin D concentrations in the blood of 749 men diagnosed with prostate cancer and 781 men who did not have the disease.
Filed under: Management, Prevention, Tips, Treatment | 1 Comment »
According to a press release from Merck & Co., an investigational agent called odanacatib (MK-0822) may be able slow the rates of breakdown and rebuilding of bone (”bone turnover”) in patients with metastatic prostate and breast cancers. Phase III clinical trials are planned in both disease states.
Filed under: Drugs in development, Management, Treatment | No Comments »
In reviewing the many prostate cancer presentations given at the AUA during last week, we have noted several that are certainly worth bringing to the attention of our readers and that have not previously been reported.
Filed under: Uncategorized | 7 Comments »
The following major new content pages have been added to the main web site over the past week:
High intensity focused ultrasound in treatment of early stage (localized) prostate cancer
Orchiectomy in treatment of metastatic prostate cancer
Luteinizing hormone releasing hormone (LHRH) agonists in treatment of metastatic prostate cancer
Luteinizing hormone releasing hormone (LHRH) antagonists in treatment of metastatic prostate cancer
Nonsteroidal [...]
Filed under: Uncategorized | No Comments »
The “New” Prostate Cancer InfoLink is pleased to announce that Judd W. Moul, MD, FACS, professor and chief, Division of Urologic Surgery, and director of the Duke Prostate Center, Duke University Health System, Durham, NC, has agreed to become the chairman of a scientific advisory board to our web services. In forthcoming weeks we [...]
Filed under: Uncategorized | No Comments »
